Autres langues Nykode Therapeutics

Actions

NYKD

NO0010714785

Recherche biotechnologique et médicale

Marché Fermé - Oslo Bors 16:45:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
3,440 ^NOK	+1,18%		-1,01%	+42,62%

28/09	Nykode Therapeutics obtient une décision défavorable du Conseil d’appel fiscal et prévoit de demander un réexamen	MT
28/08	Nykode Therapeutics lève 286 millions de couronnes norvégiennes via un placement d'actions	MT

Autres langues

28/09	Nykode Therapeutics Gets Unfavorable Tax Appeal Board Ruling, Plans to Seek Review
28/08	Nykode Therapeutics Raises NOK286 Million via Share Placement
27/08	Nykode Therapeutics ASA - Private Placement Completed
27/08	Nykode Therapeutics ASA - Contemplated Private Placement
26/08	Nykode Therapeutics : receives draft recommendation from Secretariat of Tax Appeal Board in pending tax case
26/08	Nykode Therapeutics AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
26/08	Nykode Therapeutics : reports Q2 2026 Financial Results
26/08	Nykode Therapeutics : Q2 2026 Financial Results Nykode Q2 2026 Report
20/08	Nykode Therapeutics Wins New US Patent for Neoantigen-based Cancer Vaccine
20/08	Nykode Therapeutics : Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program
06/08	Nykode Therapeutics : Grant of share options
06/08	Nykode Therapeutics Asa Announces Appointment of Jakob Helding Rasmussen as Chief Technology Officer
05/08	Nykode Therapeutics Flags Delay in Draft Recommendation for Tax Appeal in Norway
22/07	Nykode Therapeutics AS Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO
22/07	Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO
27/05	Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2026
27/05	Nykode Therapeutics : Q1 2026 Financial Results Q1 2026 Webcast presentation
27/05	Nykode Therapeutics Q1 operating loss USD 6.5 million
27/05	Nykode Therapeutics : Q1 2026 Financial Results Nykode Q1 2026 Report
27/05	Nykode Therapeutics : reports Q1 2026 Financial Results
27/05	Nykode Therapeutics - Quarterly Report Q1 2026
18/05	Nykode Therapeutics : Invitation to Q1 2026 Financial Results Presentation
18/05	Nykode Therapeutics - Invitation to Q1 2026 Financial Results Presentation
13/05	Nykode Therapeutics ASA - Minutes of Annual General Meeting
07/05	Nykode Therapeutics ASA Doses First Patient In Abili-T Phase II Randomized Trial Evaluating Abi-suva In HPV16-Positive, PD-L1-Positive Recurrent Or Metastatic Head And Neck Cancer Patients